kynurenine has been researched along with Atherosclerosis in 16 studies
Kynurenine: A metabolite of the essential amino acid tryptophan metabolized via the tryptophan-kynurenine pathway.
kynurenine : A ketone that is alanine in which one of the methyl hydrogens is substituted by a 2-aminobenzoyl group.
Atherosclerosis: A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Aim To compare serum concentrations of tryptophane (Trp) and its metabolites in subjects with no cardiovascular disease (CVD) and patients with СVD, including arterial hypertension (AH) and ischemic heart disease (IHD)." | 8.12 | Comparative analysis of tryptophan and downstream metabolites of the kynurenine and serotonin pathways in patients with arterial hypertension and coronary artery disease. ( Ageev, AA; Appolonova, SA; Belenkov, YN; Korobkova, EO; Kozhevnikova, MV; Krivova, AV; Moskaleva, NE; Privalova, EV; Shestakova, KM, 2022) |
| " Thus, we studied the correlations of aortic stiffness and echocardiographic parameters with biochemical markers and serum level of kynurenic acid (KYNA), an endothelial derivative of tryptophan, formed along the kynurenine pathway, among patients with atrial fibrillation (AF)." | 7.96 | Aortic stiffness-Is kynurenic acid a novel marker? Cross-sectional study in patients with persistent atrial fibrillation. ( Kamińska, A; Kocki, T; Urbanska, EM; Wysokiński, A; Zapolski, T, 2020) |
| " We tested the hypothesis that depressive symptoms are associated with atherosclerosis only when combined with other risk factors, such as inflammation indicated by indoleamine 2,3-dioxygenase (IDO) activation." | 7.77 | Moderating effect of indoleamine 2,3-dioxygenase (IDO) activation in the association between depressive symptoms and carotid atherosclerosis: evidence from the Young Finns study. ( Elovainio, M; Hintsa, T; Hintsanen, M; Hurme, M; Jokela, M; Keltikangas-Järvinen, L; Kivimäki, M; Lehtimäki, T; Pulkki-Råback, L; Raitakari, OT; Viikari, J, 2011) |
| "Atherosclerosis is a chronic inflammatory disease of the small and medium arteries wall caused by maladaptive local immune responses, which underpins several cardiovascular diseases (CVD)." | 6.82 | Tryptophan Metabolism in Atherosclerosis and Diabetes. ( Gluvic, Z; Isenovic, ER; Obradovic, M; Sudar-Milovanovic, E; Zaric, B, 2022) |
| "Although we are far from a complete understanding of the role of kynurenine pathway in the modulation of energy homeostasis, targeting kynurenine pathway harbors high potential to expand the range of therapies to prevent and treat metabolic diseases." | 5.01 | Emerging role for kynurenines in metabolic pathologies. ( Liu, JJ; Movassat, J; Portha, B, 2019) |
| "Aim To compare serum concentrations of tryptophane (Trp) and its metabolites in subjects with no cardiovascular disease (CVD) and patients with СVD, including arterial hypertension (AH) and ischemic heart disease (IHD)." | 4.12 | Comparative analysis of tryptophan and downstream metabolites of the kynurenine and serotonin pathways in patients with arterial hypertension and coronary artery disease. ( Ageev, AA; Appolonova, SA; Belenkov, YN; Korobkova, EO; Kozhevnikova, MV; Krivova, AV; Moskaleva, NE; Privalova, EV; Shestakova, KM, 2022) |
| " Thus, we studied the correlations of aortic stiffness and echocardiographic parameters with biochemical markers and serum level of kynurenic acid (KYNA), an endothelial derivative of tryptophan, formed along the kynurenine pathway, among patients with atrial fibrillation (AF)." | 3.96 | Aortic stiffness-Is kynurenic acid a novel marker? Cross-sectional study in patients with persistent atrial fibrillation. ( Kamińska, A; Kocki, T; Urbanska, EM; Wysokiński, A; Zapolski, T, 2020) |
| "These results indicate that Tg26/ApoE serve as a new mouse model for HIV-induced atherogenesis, and aid in understanding the role of tryptophan catabolism in the pathogenesis of HIV atherosclerosis/CVD." | 3.91 | Elevated indoleamine-2,3-dioxygenase enzyme activity in a novel mouse model of HIV-associated atherosclerosis. ( Chen, Y; Dai, S; Gordon, J; Kearns, AC; Lehmicke, G; Liu, F; Qin, X; Rappaport, J; Velasquez, S, 2019) |
| " We tested the hypothesis that depressive symptoms are associated with atherosclerosis only when combined with other risk factors, such as inflammation indicated by indoleamine 2,3-dioxygenase (IDO) activation." | 3.77 | Moderating effect of indoleamine 2,3-dioxygenase (IDO) activation in the association between depressive symptoms and carotid atherosclerosis: evidence from the Young Finns study. ( Elovainio, M; Hintsa, T; Hintsanen, M; Hurme, M; Jokela, M; Keltikangas-Järvinen, L; Kivimäki, M; Lehtimäki, T; Pulkki-Råback, L; Raitakari, OT; Viikari, J, 2011) |
| "CC-chemokines and kynurenine pathway (KP) metabolites are associated with accelerated atherosclerosis in chronic kidney disease (CKD) patients." | 3.76 | 3-hydroxyanthranilic acid is independently associated with monocyte chemoattractant protein-1 (CCL2) and macrophage inflammatory protein-1beta (CCL4) in patients with chronic kidney disease. ( Kowalewska, A; Mysliwiec, M; Pawlak, D; Pawlak, K, 2010) |
| "Atherosclerosis is a chronic inflammatory disease of the small and medium arteries wall caused by maladaptive local immune responses, which underpins several cardiovascular diseases (CVD)." | 2.82 | Tryptophan Metabolism in Atherosclerosis and Diabetes. ( Gluvic, Z; Isenovic, ER; Obradovic, M; Sudar-Milovanovic, E; Zaric, B, 2022) |
| "As asymptomatic diseases, abdominal aortic aneurysm (AAA) and atherosclerosis are associated with high morbidity and mortality." | 2.72 | Tryptophan Catabolism and Inflammation: A Novel Therapeutic Target For Aortic Diseases. ( Han, YM; Ramprasath, T; Yu, CJ; Zhang, D; Zou, MH, 2021) |
| "Atherosclerosis is a chronic inflammatory disease, in which immune disorders constitute an essential part of vascular pathogenesis." | 1.91 | Dendritic cell-expressed IDO alleviates atherosclerosis by expanding CD4 ( Cai, Z; Liu, L; Liu, M; Ma, D; Wang, F; Wang, J; Xu, Y; Zhai, C; Zhang, W; Zhao, L, 2023) |
| "Atherosclerosis is a chronic inflammatory disease that is initiated by the retention and accumulation of low-density lipoprotein in the artery, leading to maladaptive response of cells from the immune system and vessel wall." | 1.42 | Inhibition of indoleamine 2,3-dioxygenase promotes vascular inflammation and increases atherosclerosis in Apoe-/- mice. ( Agardh, H; Assinger, A; Bäck, M; Baumgartner, R; Berg, M; Gisterå, A; Hansson, GK; Ketelhuth, DF; Laguna-Fernandez, A; Ovchinnikova, O; Pirault, J; Polyzos, KA, 2015) |
| "Atherosclerosis is the major cause of cardiovascular disease (CVD), the leading cause of death worldwide." | 1.42 | Indoleamine 2,3-dioxygenase-1 is protective in atherosclerosis and its metabolites provide new opportunities for drug development. ( Astola, N; Cole, JE; Cribbs, AP; Davies, AH; Feldmann, M; Goddard, ME; Green, P; Monaco, C; Park, I; Williams, RO, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (6.25) | 29.6817 |
| 2010's | 9 (56.25) | 24.3611 |
| 2020's | 6 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Ramprasath, T | 1 |
| Han, YM | 1 |
| Zhang, D | 1 |
| Yu, CJ | 1 |
| Zou, MH | 2 |
| Ouyang, L | 1 |
| Yu, C | 1 |
| Xie, Z | 1 |
| Su, X | 1 |
| Xu, Z | 1 |
| Song, P | 1 |
| Li, J | 1 |
| Huang, H | 1 |
| Ding, Y | 1 |
| Kozhevnikova, MV | 2 |
| Krivova, AV | 2 |
| Korobkova, EO | 2 |
| Ageev, AA | 2 |
| Shestakova, KM | 2 |
| Moskaleva, NE | 2 |
| Appolonova, SA | 2 |
| Privalova, EV | 2 |
| Belenkov, YN | 2 |
| Wang, F | 1 |
| Liu, M | 1 |
| Ma, D | 1 |
| Cai, Z | 1 |
| Liu, L | 1 |
| Wang, J | 1 |
| Zhang, W | 1 |
| Zhao, L | 1 |
| Zhai, C | 1 |
| Xu, Y | 1 |
| Zapolski, T | 1 |
| Kamińska, A | 1 |
| Kocki, T | 1 |
| Wysokiński, A | 1 |
| Urbanska, EM | 1 |
| Sudar-Milovanovic, E | 1 |
| Gluvic, Z | 1 |
| Obradovic, M | 1 |
| Zaric, B | 1 |
| Isenovic, ER | 1 |
| Baumgartner, R | 2 |
| Forteza, MJ | 1 |
| Ketelhuth, DFJ | 1 |
| Liu, JJ | 1 |
| Movassat, J | 1 |
| Portha, B | 1 |
| Kearns, AC | 1 |
| Velasquez, S | 1 |
| Liu, F | 1 |
| Dai, S | 1 |
| Chen, Y | 1 |
| Lehmicke, G | 1 |
| Gordon, J | 1 |
| Rappaport, J | 1 |
| Qin, X | 1 |
| Polyzos, KA | 2 |
| Ketelhuth, DF | 2 |
| Ovchinnikova, O | 1 |
| Berg, M | 1 |
| Agardh, H | 1 |
| Pirault, J | 1 |
| Gisterå, A | 1 |
| Assinger, A | 1 |
| Laguna-Fernandez, A | 1 |
| Bäck, M | 1 |
| Hansson, GK | 1 |
| Cole, JE | 1 |
| Astola, N | 1 |
| Cribbs, AP | 1 |
| Goddard, ME | 1 |
| Park, I | 1 |
| Green, P | 1 |
| Davies, AH | 1 |
| Williams, RO | 1 |
| Feldmann, M | 1 |
| Monaco, C | 1 |
| Niinisalo, P | 1 |
| Raitala, A | 1 |
| Pertovaara, M | 1 |
| Oja, SS | 1 |
| Lehtimäki, T | 2 |
| Kähönen, M | 1 |
| Reunanen, A | 1 |
| Jula, A | 1 |
| Moilanen, L | 1 |
| Kesäniemi, YA | 1 |
| Nieminen, MS | 1 |
| Hurme, M | 2 |
| Pawlak, K | 1 |
| Kowalewska, A | 1 |
| Mysliwiec, M | 1 |
| Pawlak, D | 1 |
| Kato, A | 1 |
| Suzuki, Y | 1 |
| Suda, T | 1 |
| Suzuki, M | 1 |
| Fujie, M | 1 |
| Takita, T | 1 |
| Furuhashi, M | 1 |
| Maruyama, Y | 1 |
| Chida, K | 1 |
| Hishida, A | 1 |
| Elovainio, M | 1 |
| Jokela, M | 1 |
| Pulkki-Råback, L | 1 |
| Kivimäki, M | 1 |
| Hintsanen, M | 1 |
| Hintsa, T | 1 |
| Viikari, J | 1 |
| Raitakari, OT | 1 |
| Keltikangas-Järvinen, L | 1 |
5 reviews available for kynurenine and Atherosclerosis
| Article | Year |
|---|---|
Tryptophan Catabolism and Inflammation: A Novel Therapeutic Target For Aortic Diseases.
Topics: Animals; Anti-Inflammatory Agents; Aorta; Aortic Aneurysm, Abdominal; Aortitis; Atherosclerosis; Hum | 2021 |
Tryptophan Metabolism in Atherosclerosis and Diabetes.
Topics: Animals; Atherosclerosis; Diabetes Mellitus, Type 2; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; K | 2022 |
The interplay between cytokines and the Kynurenine pathway in inflammation and atherosclerosis.
Topics: Adaptive Immunity; Animals; Atherosclerosis; Cardiovascular Diseases; Cytokines; Humans; Immunity, I | 2019 |
Emerging role for kynurenines in metabolic pathologies.
Topics: Aging; Animals; Atherosclerosis; Biomarkers; Diabetes Mellitus; Homeostasis; Humans; Islets of Lange | 2019 |
The role of the kynurenine pathway of tryptophan metabolism in cardiovascular disease. An emerging field.
Topics: Animals; Atherosclerosis; Humans; Kynurenine; Models, Cardiovascular; Plaque, Atherosclerotic; Signa | 2015 |
11 other studies available for kynurenine and Atherosclerosis
| Article | Year |
|---|---|
Indoleamine 2,3-Dioxygenase 1 Deletion-Mediated Kynurenine Insufficiency in Vascular Smooth Muscle Cells Exacerbates Arterial Calcification.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Core Binding Factor Alpha 1 Subunit; Humans; Indoleamin | 2022 |
Comparative analysis of tryptophan and downstream metabolites of the kynurenine and serotonin pathways in patients with arterial hypertension and coronary artery disease.
Topics: Atherosclerosis; Coronary Artery Disease; Humans; Hydroxyindoleacetic Acid; Hypertension; Kynurenic | 2022 |
Comparative analysis of tryptophan and downstream metabolites of the kynurenine and serotonin pathways in patients with arterial hypertension and coronary artery disease.
Topics: Atherosclerosis; Coronary Artery Disease; Humans; Hydroxyindoleacetic Acid; Hypertension; Kynurenic | 2022 |
Comparative analysis of tryptophan and downstream metabolites of the kynurenine and serotonin pathways in patients with arterial hypertension and coronary artery disease.
Topics: Atherosclerosis; Coronary Artery Disease; Humans; Hydroxyindoleacetic Acid; Hypertension; Kynurenic | 2022 |
Comparative analysis of tryptophan and downstream metabolites of the kynurenine and serotonin pathways in patients with arterial hypertension and coronary artery disease.
Topics: Atherosclerosis; Coronary Artery Disease; Humans; Hydroxyindoleacetic Acid; Hypertension; Kynurenic | 2022 |
Dendritic cell-expressed IDO alleviates atherosclerosis by expanding CD4
Topics: Animals; Atherosclerosis; Dendritic Cells; Forkhead Transcription Factors; Indoleamine-Pyrrole 2,3,- | 2023 |
Aortic stiffness-Is kynurenic acid a novel marker? Cross-sectional study in patients with persistent atrial fibrillation.
Topics: Adult; Aorta; Atherosclerosis; Atrial Fibrillation; Biomarkers; Cross-Sectional Studies; Echocardiog | 2020 |
Elevated indoleamine-2,3-dioxygenase enzyme activity in a novel mouse model of HIV-associated atherosclerosis.
Topics: Animals; Aorta; Aortic Diseases; Atherosclerosis; Cytokines; Diet, High-Fat; Disease Models, Animal; | 2019 |
Inhibition of indoleamine 2,3-dioxygenase promotes vascular inflammation and increases atherosclerosis in Apoe-/- mice.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Inflammat | 2015 |
Indoleamine 2,3-dioxygenase-1 is protective in atherosclerosis and its metabolites provide new opportunities for drug development.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Cinnamates; Drug Design; Indoleamine-Pyrrole 2,3,-Dioxy | 2015 |
Indoleamine 2,3-dioxygenase activity associates with cardiovascular risk factors: the Health 2000 study.
Topics: Adult; Aged; Atherosclerosis; Cardiovascular Diseases; Female; Health; Humans; Indoleamine-Pyrrole 2 | 2008 |
3-hydroxyanthranilic acid is independently associated with monocyte chemoattractant protein-1 (CCL2) and macrophage inflammatory protein-1beta (CCL4) in patients with chronic kidney disease.
Topics: 3-Hydroxyanthranilic Acid; Adult; Aged; Atherosclerosis; Chemokine CCL2; Chemokine CCL4; Chemokines, | 2010 |
Relationship between an increased serum kynurenine/tryptophan ratio and atherosclerotic parameters in hemodialysis patients.
Topics: Adult; Aged; Ankle Brachial Index; Atherosclerosis; Carotid Arteries; Female; Humans; Indoleamine-Py | 2010 |
Moderating effect of indoleamine 2,3-dioxygenase (IDO) activation in the association between depressive symptoms and carotid atherosclerosis: evidence from the Young Finns study.
Topics: Adult; Atherosclerosis; Carotid Artery Diseases; Depression; Dioxygenases; Female; Humans; Indoleami | 2011 |